Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Clinical Evaluation of the BIOFIRE SPOTFIRE Respiratory Panel.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI
    • Subject Terms:
      COVID-19*/diagnosis ; COVID-19*/virology ; Respiratory Tract Infections*/virology ; Respiratory Tract Infections*/diagnosis ; SARS-CoV-2*/genetics ; SARS-CoV-2*/isolation & purification; Humans ; Hong Kong ; Sensitivity and Specificity ; Molecular Diagnostic Techniques/methods ; COVID-19 Nucleic Acid Testing/methods
    • Abstract:
      The BIOFIRE SPOTFIRE Respiratory (R) Panel is a novel, in vitro diagnostic PCR assay with 15 pathogen targets. The runtime is about 15 min which is the shortest among similar panels in the market. We evaluated the performance of the SPOTFIRE R Panel with 151 specimens, including 133 collected from the upper respiratory tract (URT), 13 from the lower respiratory tract (LRT) and 5 external quality assessment program (EQAP) samples. The respiratory specimens were enrolled throughout the first two post-COVID-19 influenza seasons in Hong Kong (March to December 2023). For URT specimens, full concordance was observed between the SPOTFIRE R Panel and the standard-of-care FilmArray Respiratory 2.1 plus Panel (RP2.1 plus ) for 109 specimens (109/133, 81.95%). After discrepant analysis, the SPOTFIRE R Panel identified more pathogens than the RP2.1 plus in 15 specimens and vice versa in 3 specimens. The per-target negative and positive percentage agreement (NPA and PPA) were 92.86-100% except the PPA of adenovirus (88.24%). For LRT and EQAP samples, all results were fully concordant. To conclude, the performance of the SPOTFIRE R Panel was comparable to the RP2.1 plus .
    • References:
      IDCases. 2020 Apr 20;20:e00762. (PMID: 32368493)
      EClinicalMedicine. 2021 Jun 28;37:100986. (PMID: 34386754)
      Adv Ther. 2023 Apr;40(4):1601-1627. (PMID: 36790682)
      Influenza Other Respir Viruses. 2023 Apr 23;17(4):e13134. (PMID: 37102059)
      Influenza Other Respir Viruses. 2023 Jun;17(6):e13171. (PMID: 37380176)
      Lancet Respir Med. 2015 Feb;3(2):139-149. (PMID: 25481379)
      Lancet Respir Med. 2024 Jan;12(1):1. (PMID: 38101434)
      Infect Dis Ther. 2021 Mar;10(1):335-346. (PMID: 33270206)
      Front Cell Infect Microbiol. 2023 Jun 14;13:1208235. (PMID: 37389220)
      Viruses. 2023 Aug 26;15(9):. (PMID: 37766227)
      Cureus. 2022 Apr 28;14(4):e24563. (PMID: 35664402)
      Ann Clin Microbiol Antimicrob. 2021 Aug 24;20(1):55. (PMID: 34429126)
      PLoS One. 2007 Oct 03;2(10):e966. (PMID: 17912345)
      BMC Pulm Med. 2022 May 30;22(1):212. (PMID: 35637540)
      J Infect. 2011 Oct;63(4):260-6. (PMID: 21546090)
      J Clin Microbiol. 1999 May;37(5):1288-93. (PMID: 10203472)
      J Epidemiol Glob Health. 2024 Mar;14(1):1-3. (PMID: 38079096)
      J Clin Microbiol. 2020 May 26;58(6):. (PMID: 32269103)
    • Contributed Indexing:
      Keywords: BIOFIRE; FilmArray; PCR; SARS-CoV-2; SPOTFIRE; TORCH; flu; respiratory
    • Publication Date:
      Date Created: 20240427 Date Completed: 20240427 Latest Revision: 20240522
    • Publication Date:
      20240522
    • Accession Number:
      PMC11055108
    • Accession Number:
      10.3390/v16040600
    • Accession Number:
      38675941